HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More Patients

Overview of the management of HER2-low breast cancer patientsПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast CancerПодробнее

Remaining questions on the management of HER2-low breast cancerПодробнее

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and MoreПодробнее

Remaining questions surrounding HER2-low breast cancer – how low can you go?Подробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

HER2-low expression in breast cancerПодробнее

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancerПодробнее

Defining HER2-low breast cancer as a clinical subtypeПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее

Highlights in HER2-low breast cancer at SABCS 2022Подробнее

Latest news in HER2-low breast cancerПодробнее

Treatment Options for HER2-Low Breast Cancer: All You Need to KnowПодробнее

Remaining questions regarding HER2-low breast cancerПодробнее